Epiphron Capital
Overview
Epiphron Capital is an international equity investment firm focused on the biotechnology and life sciences sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| LakeShore Biopharma Co., Ltd. | Jun 2026 | Take Private | Co-investor |
| Clarapath | Nov 2021 | Series B | Co-investor |
| Inmagene | Jun 2021 | Series C | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Epiphron Capital based?
Epiphron Capital is headquartered in Beijing, China.
When was Epiphron Capital founded?
Epiphron Capital was founded in 2016.
How many portfolio companies does Epiphron Capital have?
Epiphron Capital has 3 portfolio companies in Caplight's dataset.
What are some companies in Epiphron Capital's portfolio?
Recent investments visible on Caplight include LakeShore Biopharma Co., Ltd., Clarapath, Inmagene, LakeShore Biopharma Co., Ltd..
What was Epiphron Capital's most recent investment?
Epiphron Capital's most recent investment on Caplight was in LakeShore Biopharma Co., Ltd. in 2026.
What sectors does Epiphron Capital focus on?
Epiphron Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Epiphron Capital focus on?
Epiphron Capital typically invests at the Mid stage.
What is Epiphron Capital's AUM?
Epiphron Capital's assets under management are estimated between $0.0 and $50.0M.